|
|
|
|
LEADER |
03231nam a2200613Ia 4500 |
001 |
10.3390-molecules27072281 |
008 |
220425s2022 CNT 000 0 und d |
020 |
|
|
|a 14203049 (ISSN)
|
245 |
1 |
0 |
|a Isolation and In Silico SARS-CoV-2 Main Protease Inhibition Potential of Jusan Coumarin, a New Dicoumarin from Artemisia glauca
|
260 |
|
0 |
|b MDPI
|c 2022
|
856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.3390/molecules27072281
|
520 |
3 |
|
|a A new dicoumarin, jusan coumarin, (1), has been isolated from Artemisia glauca aerial parts. The chemical structure of jusan coumarin was estimated, by 1D, 2D NMR as well as HR-Ms spectroscopic methods, to be 7-hydroxy-6-methoxy-3-[(2-oxo-2H-chromen-6-yl)oxy]-2H-chromen-2-one. As the first time to be introduced in nature, its potential against SARS-CoV-2 has been estimated using various in silico methods. Molecular similarity and fingerprints experiments have been utilized for 1 against nine co-crystallized ligands of COVID-19 vital proteins. The results declared a great similarity between Jusan Coumarin and X77, the ligand of COVID-19 main protease (PDB ID: 6W63), Mpro . To authenticate the obtained outputs, a DFT experiment was achieved to confirm the similarity of X77 and 1. Consequently, 1 was docked against Mpro . The results clarified that 1 bonded in a correct way inside Mpro active site, with a binding energy of −18.45 kcal/mol. Furthermore, the ADMET and toxicity profiles of 1 were evaluated and showed the safety of 1 and its likeness to be a drug. Finally, to confirm the binding and understand the thermodynamic characters between 1 and Mpro, several molecular dynamics (MD) simulations studies have been administered. Additionally, the known coumarin derivative, 7-isopentenyloxycoumarin (2), has been isolated as well as β-sitosterol (3). © 2022 by the authors. Licensee MDPI, Basel, Switzerland.
|
650 |
0 |
4 |
|a 3C-like proteinase, SARS-CoV-2
|
650 |
0 |
4 |
|a ADMET
|
650 |
0 |
4 |
|a Artemisia
|
650 |
0 |
4 |
|a Artemisia
|
650 |
0 |
4 |
|a Artemisia glauca
|
650 |
0 |
4 |
|a chemistry
|
650 |
0 |
4 |
|a Coronavirus 3C Proteases
|
650 |
0 |
4 |
|a coumarin
|
650 |
0 |
4 |
|a coumarin derivative
|
650 |
0 |
4 |
|a Coumarins
|
650 |
0 |
4 |
|a COVID-19
|
650 |
0 |
4 |
|a COVID-19 main protease
|
650 |
0 |
4 |
|a DFT
|
650 |
0 |
4 |
|a dicoumarol
|
650 |
0 |
4 |
|a Dicumarol
|
650 |
0 |
4 |
|a drug therapy
|
650 |
0 |
4 |
|a jusan coumarin
|
650 |
0 |
4 |
|a ligand
|
650 |
0 |
4 |
|a Ligands
|
650 |
0 |
4 |
|a molecular docking
|
650 |
0 |
4 |
|a Molecular Docking Simulation
|
650 |
0 |
4 |
|a molecular dynamics
|
650 |
0 |
4 |
|a molecular dynamics
|
650 |
0 |
4 |
|a Molecular Dynamics Simulation
|
650 |
0 |
4 |
|a molecular similarity
|
650 |
0 |
4 |
|a new dicoumarin
|
650 |
0 |
4 |
|a Protease Inhibitors
|
650 |
0 |
4 |
|a proteinase inhibitor
|
650 |
0 |
4 |
|a SARS-CoV-2
|
650 |
0 |
4 |
|a structure fingerprint
|
650 |
0 |
4 |
|a toxicity
|
700 |
1 |
|
|a Alsfouk, A.A.
|e author
|
700 |
1 |
|
|a Dehaen, W.
|e author
|
700 |
1 |
|
|a Eissa, I.H.
|e author
|
700 |
1 |
|
|a Elkaeed, E.B.
|e author
|
700 |
1 |
|
|a Ishmuratova, M.Y.
|e author
|
700 |
1 |
|
|a Jose, R.A.
|e author
|
700 |
1 |
|
|a Metwaly, A.M.
|e author
|
700 |
1 |
|
|a Suleimen, R.N.
|e author
|
700 |
1 |
|
|a Suleimen, Y.M.
|e author
|
700 |
1 |
|
|a Toppet, S.
|e author
|
773 |
|
|
|t Molecules
|